Sun Pharma enters Japanese Prescription Market

Novartis and Sun
Pharma agreed to a novel transaction conceptualized by MP team. Sun Pharma
acquired 14 long-listed brands in Japan from Novartis for a total cash
consideration of $293 million (see Press Release below). MP Advisors, led by
Tarun Shah, solved a challenge facing many biopharma companies—how to establish
a significant presence in Japan that will create a sustainable and growing

MP team is
well-positioned to help you solve such challenges in capturing global growth
opportunities, from major established countries to emerging countries.

We invite your inquiry
as to how we can join hands with you to create unique opportunities.

Sun Pharma enters
Japanese prescription market

Strategic acquisition
of 14 prescription brands

Mumbai, March 29,
2016: Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE:
524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or
associate companies) today announced the acquisition of 14 established
prescription brands from Novartis AG and Novartis Pharma AG (together
‘Novartis’) in Japan.

According to the
agreements entered into between the parties, a wholly-owned subsidiary of Sun
Pharma will acquire the portfolio consisting of 14 established prescription
brands from Novartis for a cash consideration of US$ 293 million. These brands
have combined annualized revenues of approximately US$ 160 million and address
medical conditions across several therapeutic areas. Under the terms of the
agreements, Novartis will continue to distribute these brands, for a certain
period, pending transfer of all marketing authorizations to Sun Pharma’s
subsidiary. The acquired brands will be marketed by a reliable and established
local marketing partner under the Sun Pharma label. The local marketing partner
will also be responsible for distribution of the brands.

Commenting on the
acquisition, Dilip Shanghvi, Managing Director, Sun Pharma said, “Japan is a
market of strategic interest for us. This acquisition marks Sun Pharma’s foray
into the Japanese prescription market and provides us an opportunity to build a
larger product portfolio in the future.”

As per the
December-2015 IMS Data, the size of the Japanese pharmaceutical market was
estimated at US$ 73 Billion, accounting for over 7% of the US$ 1 Trillion
global pharmaceutical market.

About Sun
Pharmaceutical Industries Ltd. (CIN – L24230GJ1993PLC019050) Sun Pharma is the
world’s fifth largest specialty generic pharmaceutical company and India’s top
pharmaceutical company. A vertically integrated business, economies of scale
and an extremely skilled team enable us to deliver quality products in a timely
manner at affordable prices. It provides high-quality, affordable medicines
trusted by customers and patients in over 150 countries across the world. Sun
Pharma’s global presence is supported by 49 manufacturing facilities spread
across 6 continents, R&D centres across the globe and a multi-cultural
workforce comprising over 50 nationalities.

The consolidated revenues
for 12 months ending March 2015 are approximately US$ 4.5 billion, of which US
contributes US$ 2.2 billion. In India, the company enjoys leadership across 12
different classes of doctors with 30 brands featuring amongst top 300
pharmaceutical brands in India. Its footprint across emerging markets covers over
100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare
business is ranked amongst Top 10 across 4 global markets. Its API business
footprint is strengthened through 14 world class API manufacturing facilities
across the globe. Sun Pharma fosters excellence through innovation supported by
strong R&D capabilities comprising about 2,000 scientists and R&D
investments of over 7% of annual revenues.

Leave a Reply

Close Menu